HHS AWARDS CONTRACT TO BAVARIAN NORDIC FOR THE CONTINUED DEVELOPMENT OF A FREEZE-DRIED FORMULATION OF THE IMVAMUNE(r) SMALLPOX VACCINE

HHS AWARDS CONTRACT TO BAVARIAN NORDIC FOR THE CONTINUED DEVELOPMENT OF A FREEZE-DRIED FORMULATION OF THE IMVAMUNE(r) SMALLPOX VACCINE


On November 16, 2009, the Biomedical Advanced Research and Development Authority (BARDA) awarded an advanced research and development contract to Bavarian Nordic A/S of Copenhagen, Denmark to continue the development of a freeze-dried formulation of the next generation modified vaccinia Ankara (MVA) smallpox vaccine destined for the Strategic National Stockpile.

Bavarian Nordic is currently under a Project BioShield contract to manufacture and deliver 20 million doses of MVA (trade name IMVAMUNE(r)) liquid frozen smallpox vaccine to address at-risk individuals. The freeze-dried formulation will have an improved shelf-life, reduced storage costs, and simplified transport logistics as compared to the current liquid frozen formulation.

This is the first advanced research and development contract awarded under the Broad Agency Announcement (BAA-BARDA-09-34) "Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures". This Broad Agency Announcement provides a means to identify innovative and promising technologies for advanced development across the Chemical, Biological, Radiological and Nuclear research areas of interest, focusing on technology readiness levels 6 to 7 (Pre-Investigational New Drug to Phase 2). The current research areas of interest include vaccines, antitoxins and therapeutics, antimicrobial drugs, radiological/nuclear threat countermeasures, chemical threat countermeasures, and clinical diagnostic tools.

The development of the freeze-dried formulation will build upon the MVA smallpox vaccine research and development efforts initiated by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the Project BioShield contract under BARDA.

abrir aquí:
HHS AWARDS CONTRACT TO BAVARIAN NORDIC FOR THE CONTINUED DEVELOPMENT OF A FREEZE-DRIED FORMULATION OF THE IMVAMUNE(r) SMALLPOX VACCINE